TLT.V - Theralase Technologies Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.5400
+0.0500 (+10.20%)
As of 10:45AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.4900
Open0.5100
Bid0.5200 x 0
Ask0.5400 x 0
Day's Range0.5100 - 0.5400
52 Week Range0.2000 - 0.6000
Volume219,779
Avg. Volume455,983
Market Cap78.398M
Beta (3Y Monthly)2.32
PE Ratio (TTM)N/A
EPS (TTM)-0.0260
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.38
  • ACCESSWIRE4 hours ago

    Theralase's Latest Scientific Research to be Presented at the 17th Annual International Photodynamic Association World Congress

    Nine Scientific Papers Detailing the Latest Scientific Research of Theralase ® 's Anti-Cancer Technology ("ACT") Platform have been Peer Reviewed and will be Presented at the International Photodynamic ...

  • Is Theralase Technologies's (CVE:TLT) 132% Share Price Increase Well Justified?
    Simply Wall St.4 days ago

    Is Theralase Technologies's (CVE:TLT) 132% Share Price Increase Well Justified?

    When you buy shares in a company, there is always a risk that the price drops to zero. But if you pick the right stock, you can make a lot more than 100%. For example, the Theralase Technologies Inc. (CVE:TLT) share pric...

  • ACCESSWIRE5 days ago

    Theralase(R) Releases 2018 Year End Audited Financial Statements

    TORONTO, ON / ACCESSWIRE / April 17, 2019 /Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds ("PDC") and their associated drug formulations intended to safely and effectively destroy various cancers released the audited financial statements for the year ended December 31, 2018. In the US, revenue increased 16% to $304,785 from $261,833 and international revenue increased 62% to $223,975 from $138,665. The decrease in total revenue in 2018 is primarily due to the restructuring of the sales and marketing departments resulting in the termination of certain sales and marketing personnel and decreased spending in advertising.

  • ACCESSWIRE20 days ago

    Patient Six Cancer-Free Twelve Months After Single Anti-Cancer Treatment

    Results of Phase Ib Non-Muscle Invasive Bladder Cancer ("NMIBC") Clinical Study Demonstrate a 66% Complete Response ("CR") at the Therapeutic Dose (0.70 mg/cm2) 360 Days Post Treatment ...

  • ACCESSWIRE27 days ago

    Theralase’s Phase IB Clinical Study to be Presented at the 17(th) International Photodynamic Association World Congress

    TORONTO, ON / ACCESSWIRE / MARCH 26, 2019 /Theralase Technologies Inc. ("Theralase®" or the "Company") (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated PhotoDynamic Compounds ("PDC") and their associated drug formulations intended to safely and effectively destroy various cancers is pleased to announce that the results of the Phase Ib clinical study will be presented at the 17th International Photodynamic Association ("IPA") World Congress, to be held in Cambridge, Massachusetts from June 28th to July 4th, 2019. IPA has been bringing together researchers and clinicians in all fields of PhotoDynamic Therapy ("PDT") and PhotoDiagnosis ("PD") since 1986.

  • ACCESSWIRE2 months ago

    Theralase Granted United States Patent to Destroy Cancer Cells with X-Ray Activated Photo Dynamic Compounds

    TORONTO, ONTRAIO / ACCESSWIRE / March 4, 2019 / Theralase Technologies Inc. ("Theralase®" or the "Company") (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds ("PDCs") and their associated drug formulations intended to safely and effectively destroy various cancers, announced today that it has been granted allowance for a United States patent to issue later this year for destroying cancer cells with X-ray activated PDCs. Arkady Mandel, M.D., Ph.D., D.Sc., Chief Scientific Officer of Theralase® and the lead inventor of the technology stated that, "In 2019, the Company plans to commence a Phase II Non-Muscle Invasive Bladder Cancer ("NMIBC") clinical study, which if successful may lead to commercialization of this technology in Canada, the United States and the European Union.

  • ACCESSWIRE2 months ago

    Theralase Named to 2019 TSX Venture 50(TM)

    TORONTO, ON / ACCESSWIRE / February 28, 2019 / Theralase Technologies Inc. ("Theralase®" or the "Company") (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated photo dynamic compounds and their associated drug formulations intended to safely and effectively destroy various cancers has been named third place on the 2019 TSX Venture 50TM in the Clean Technology & Life Sciences sector amongst all TSX Venture Exchange listed companies. The ranking is comprised of ten companies from each of five industry sectors, selected based on three equally weighted criteria: market capitalization growth, share price appreciation and trading volume amount.

  • ACCESSWIRE2 months ago

    Theralase Announces Appointment of New Chief Executive Officers

    TORONTO, ON / ACCESSWIRE / February 25, 2019 / Theralase Technologies Inc. (" Theralase ® " or the " Company ") ( TSXV: TLT ) ( OTCQB: TLTFF ), a clinical stage pharmaceutical company ...

  • ACCESSWIRE3 months ago

    Patient Five Cancer-Free Twelve Months After Single Anti-Cancer Treatment

    TORONTO, ON / ACCESSWIRE / January 31, 2019 / Theralase Technologies Inc. ("Theralase®" or the "Company") (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds ("PDCs") and their associated drug formulations intended to safely and effectively destroy various cancers reports that patient five, enrolled and treated in the recently completed Phase Ib Non-Muscle Invasive Bladder Cancer ("NMIBC") clinical study ("Study"), has demonstrated no tumour recurrence or presence of disease at the 360 day clinical and cystoscopy assessment. The Study's purpose was to evaluate TLD-1433, Theralase's lead PDC, for the primary endpoint of safety and tolerability, secondary endpoint of pharmacokinetics (movement and exit of drug within tissue) and exploratory endpoint of efficacy, primarily at 90 days and secondarily at 180 days post treatment.

  • ACCESSWIRE3 months ago

    Patient Six Cancer-Free at Nine Months After Single Anti-Cancer Treatment

    TORONTO, ON / ACCESSWIRE / January 30, 2019 / Theralase Technologies Inc. ("Theralase®" or the "Company") (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds ("PDCs") and their associated drug formulations intended to safely and effectively destroy various cancers reports that patient six, enrolled and treated in the recently completed Phase Ib Non-Muscle Invasive Bladder Cancer ("NMIBC") clinical study ("Study"), has demonstrated no tumour recurrence or presence of disease at the 270 day clinical and cystoscopy assessment. The Study's purpose was to evaluate TLD-1433, Theralase's lead PDC, for the primary endpoint of safety and tolerability, secondary endpoint of pharmacokinetics (movement and exit of drug within tissue) and exploratory endpoint of efficacy, primarily at 90 days and secondarily at 180 days post treatment.

  • ACCESSWIRE4 months ago

    Health Canada Grants ITA Approval to Commence Phase II Clinical Study

    TORONTO, ON / ACCESSWIRE / December 10, 2018 / Theralase Technologies Inc.(" Theralase® " or the " Company ") ( TSXV: TLT ) ( OTCQB: TLTFF ), a clinical stage pharmaceutical company ...

  • ACCESSWIRE5 months ago

    Theralase(R) Granted Canadian Anti-Cancer Patent

    Theralase Granted Canadian Patent for Metal-Glycoprotein Complexes Used to Hunt Cancer Cells and When Laser Light Activated Destroy Them TORONTO, ON / ACCESSWIRE / November 15, 2018 / Theralase Technologies ...

  • ACCESSWIRE5 months ago

    Patient Five Cancer-Free After Single PDT Treatment

    Theralase Provides Update on 9 Months Post Treatment Cystoscopy Analysis TORONTO, ONTARIO / ACCESSWIRE / November 8, 2018 / Theralase Technologies Inc. (" Theralase® " or the " Company ")( ...

  • Newsfile9 months ago

    BTV Reveals Novel Cancer Treatment, Cannabis and Lithium Companies

    Vancouver, British Columbia--(Newsfile Corp. - July 26, 2018) - On BNN Sat July 28 & Sun July 29, 2018 - BTV-Business Television goes on location with four small cap companies in popular sectors. Full EpisodeBlissCo Cannabis Corp. (CSE: BLIS) — BTV shares how this CEO's distribution background will help his company profit in the rapidly expanding cannabis market. See Feature  Critical Elements Corp. (TSXV: CRE) (OTCQX: CRECF) — Electric vehicle demand spells opportunity for the key ...